Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Anebulo Pharmaceuticals ( (ANEB) ) is now available.
On September 12, 2025, Anebulo Pharmaceuticals announced an update on its going private transaction and strategic alternatives. The company is exploring various options, including a reverse stock split, asset sale, or merger, to maximize stockholder value. Despite receiving interest from potential partners, there is no assurance of a transaction, and the timeline for the strategic review remains undefined.
The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
Spark’s Take on ANEB Stock
According to Spark, TipRanks’ AI Analyst, ANEB is a Underperform.
Anebulo Pharmaceuticals is struggling financially, with no revenue generation and consistent losses. The technical indicators reflect a bearish trend, with the stock trading below key moving averages. Valuation metrics are weak due to negative earnings. While the balance sheet is strong with no debt, the heavy reliance on financing activities poses a risk. Investors should be cautious and consider the company’s ability to achieve profitability and secure future funding.
To see Spark’s full report on ANEB stock, click here.
More about Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial for acute cannabinoid intoxication and is being developed in an intravenous formulation for pediatric patients.
Average Trading Volume: 413,369
Technical Sentiment Signal: Hold
Current Market Cap: $82.58M
For an in-depth examination of ANEB stock, go to TipRanks’ Overview page.